Rgenta Therapeutics
PrivateLast Round
Series A
Nov 29, 2022
Total Funding Raised
$90M
Company Overview
Rgenta Therapeutics is a biotechnology company that develops oral, small-molecule RNA-targeting medicines for oncology and neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Rgenta Therapeutics Comparables
Compare Rgenta Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Remix Therapeutics | 88% | |
| Arrakis Therapeutics | 86% | |
| Accent Therapeutics | 84% |
Rgenta Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 29, 2022 | ||||
| Seed | May 25, 2021 | ||||
| Seed | Apr 2, 2020 |
Rgenta Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Matrix | Series A, Seed |
| Legend Star | Seed |
| Korea Investment Partners | Series A |
| Kaitai Capital | Seed, Series A |
| MPC | Series A, Seed |
| Boehringer Ingelheim Venture Fund | Series A, Seed |
| Lilly Asia Ventures | Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Phase 1a/b study data released for oral MYB splicing modulator RGT-61159.
- Apr 21, 2026
Abstract accepted for poster presentation at the 2026 ASCO Annual Meeting.
Rgenta Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Rgenta Therapeutics's valuation, stock price, and market status.
Is Rgenta Therapeutics a public or private company?
Rgenta Therapeutics is a private company.
What is the current stock price of Rgenta Therapeutics?
Rgenta Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Rgenta Therapeutics worth (valuation)?
Valuation information for Rgenta Therapeutics is not publicly available.
Can I buy Rgenta Therapeutics stock?
Rgenta Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Rgenta Therapeutics's last funding round?
Rgenta Therapeutics's most recent funding round was Series A on November 29, 2022.
Who are the main investors in Rgenta Therapeutics?
Key investors in Rgenta Therapeutics include Matrix, Boehringer Ingelheim Venture Fund, CICC Fund.
Will Rgenta Therapeutics IPO soon?
No public IPO plans have been announced for Rgenta Therapeutics.
How can I track Rgenta Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Rgenta Therapeutics's secondary market activity and sign up for updates.